[ET Net News Agency, 24 September 2021] Sihuan Pharmaceutical Holdings Group Ltd.
(00460) said its subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharm) and
SignalChem Lifesciences Corporation (SignalChem) have entered into a collaboration and
licensing agreement for the development and commercialization interests of SLC-391, a
highly potent and highly selective AXL targeting inhibitor, in the Greater China region.
Xuanzhu Biopharm will pay SignalChem an upfront fee of US$13 million. In addition,
SignalChem is entitled to receive milestone payments including development, registration
and commercialization, and royalties in the future. The group will obtain the exclusive
research, development, manufacture and commercialization rights for each indication of
SLC-391 in the field of oncology in the Greater China region. (RC)